You are here

  • Home
  • Archive
  • Volume 76, Issue 6
  • A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis

Citation Tools

Article menu

Download PDFPDF

Clinical and epidemiological research
Extended report
A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Burmester GR, McInnes IB, Kremer J on behalf of the EARTH EXPLORER 1 study investigators, et al
A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis
Annals of the Rheumatic Diseases 2017;76:1020-1030.